{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T14:56:40Z","timestamp":1780066600519,"version":"3.54.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1038\/s41433-025-03753-x","type":"journal-article","created":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T04:00:12Z","timestamp":1742875212000},"page":"1825-1830","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Spectrum of presentation of intraocular metastases from cutaneous melanoma in the era of immunotherapy and targeted therapies"],"prefix":"10.1038","volume":"39","author":[{"given":"St\u00e9phanie","family":"Lema\u00eetre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit K.","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon Robert","family":"Hay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1530-3824","authenticated-orcid":false,"given":"Mandeep S.","family":"Sagoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"key":"3753_CR1","first-page":"45","volume":"121","author":"N Eisemann","year":"2024","unstructured":"Eisemann N, Schumann L, Baltus H, Labohm L, Kraywinkel K, Katalinic A. Longer survival from melanoma in Germany. Dtsch Arztebl Int. 2024;121:45\u201351.","journal-title":"Dtsch Arztebl Int"},{"issue":"Suppl 10","key":"3753_CR2","doi-asserted-by":"publisher","first-page":"x101","DOI":"10.1093\/annonc\/mds308","volume":"23","author":"R Dummer","year":"2012","unstructured":"Dummer R, Rozati S, Eggmann N, Rinderknecht J, Goldinger SM. From chemotherapy to targeted treatment. Ann Oncol. 2012;23:x101\u20133.","journal-title":"Ann Oncol"},{"key":"3753_CR3","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1056\/NEJMoa1904059","volume":"381","author":"C Robert","year":"2019","unstructured":"Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019;381:626\u201336.","journal-title":"N Engl J Med"},{"key":"3753_CR4","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J-J, Rutkowski P, Lao CD, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381:1535\u201346.","journal-title":"N Engl J Med"},{"key":"3753_CR5","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/CMR.0000000000000591","volume":"29","author":"AB Fernandez-Diaz","year":"2019","unstructured":"Fernandez-Diaz AB, Garc\u00eda-Medina A, Ferrer-Guillen B, Berrocal A. Eye immune privilege? Nivolumab plus ipilimumab: successful treatment in a patient with cutaneous melanoma and ocular metastases. Melanoma Res. 2019;29:345\u20137.","journal-title":"Melanoma Res"},{"key":"3753_CR6","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1097\/IAE.0000000000003038","volume":"41","author":"E Szalai","year":"2021","unstructured":"Szalai E, Csutak A, Lengyel Z. Complete resolution of bilateral choroidal metastases of cutaneous melanoma with combined targeted therapy. Retina. 2021;41:e30\u20131.","journal-title":"Retina"},{"key":"3753_CR7","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1159\/000511187","volume":"7","author":"A Venkat","year":"2021","unstructured":"Venkat A, Binkley EM, Srivastava S, Karthik N, Singh AD. Immunotherapy-resistant vitreoretinal metastatic melanoma. Ocul Oncol Pathol. 2021;7:62\u20135.","journal-title":"Ocul Oncol Pathol"},{"key":"3753_CR8","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1097\/CMR.0000000000000443","volume":"28","author":"DIT Sia","year":"2018","unstructured":"Sia DIT, Thaung C, O\u2019Hanlon-Brown C, Cohen VML, Sagoo MS. Immune privilege: failure of immunotherapy in controlling metastatic cutaneous melanoma to the eye. Melanoma Res. 2018;28:359\u201362.","journal-title":"Melanoma Res"},{"key":"3753_CR9","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00417-013-2563-5","volume":"252","author":"RS Grajewski","year":"2014","unstructured":"Grajewski RS, Schuler-Thurner B, Mauch C, Kreuzberg N, Koch KR, Bergua A, et al. Ocular diseases in metastatic cutaneous melanoma: review of 108 consecutive patients in two German tertiary centers. Graefes Arch Clin Exp Ophthalmol. 2014;252:679\u201385.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3753_CR10","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1093\/jnci\/djz153","volume":"112","author":"AP Thrift","year":"2020","unstructured":"Thrift AP, Gudenkauf FJ. Melanoma incidence among non-Hispanic Whites in all 50 US states from 2001 through 2015. J Natl Cancer Inst. 2020;112:533\u20139.","journal-title":"J Natl Cancer Inst"},{"key":"3753_CR11","first-page":"344","volume":"156","author":"R Pampena","year":"2021","unstructured":"Pampena R, Michelini S, Lai M, Chester J, Pellacani G, Longo C. New systemic therapies for cutaneous melanoma: why, who and what. Ital J Dermatol Venerol. 2021;156:344\u201355.","journal-title":"Ital J Dermatol Venerol"},{"key":"3753_CR12","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/CCO.0000000000000296","volume":"28","author":"J Antoun","year":"2016","unstructured":"Antoun J, Titah C, Cochereau I. Ocular and orbital side-effects of checkpoint inhibitors: a review article. Curr Opin Oncol. 2016;28:288\u201394.","journal-title":"Curr Opin Oncol"},{"key":"3753_CR13","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1097\/IAE.0000000000002451","volume":"39","author":"S M\u00e9ndez-Mart\u00ednez","year":"2019","unstructured":"M\u00e9ndez-Mart\u00ednez S, Calvo P, Ruiz-Moreno O, Pardi\u00f1as Bar\u00f3n N, Leci\u00f1ena Bueno J, Gil Ruiz MDR, et al. Ocular adverse events associated with MEK inhibitors. Retina. 2019;39:1435\u201350.","journal-title":"Retina"},{"key":"3753_CR14","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.jfo.2021.08.005","volume":"45","author":"E Fauviaux","year":"2022","unstructured":"Fauviaux E, Promelle V, Boucenna V, Jany B, Errera MH, Delbarre M, et al. [Ocular toxicity of targeted therapies with MEK inhibitors and BRAF inhibitors in the treatment of metastatic cutaneous melanoma]. J Fr Ophtalmol. 2022;45:612\u20138.","journal-title":"J Fr Ophtalmol"},{"key":"3753_CR15","doi-asserted-by":"publisher","first-page":"122","DOI":"10.4103\/0301-4738.154380","volume":"63","author":"S Arepalli","year":"2015","unstructured":"Arepalli S, Kaliki S, Shields CL. Choroidal metastases: origin, features, and therapy. Indian J Ophthalmol. 2015;63:122\u20137.","journal-title":"Indian J Ophthalmol"},{"key":"3753_CR16","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.survophthal.2008.02.003","volume":"53","author":"C Rosenberg","year":"2008","unstructured":"Rosenberg C, Finger PT. Cutaneous malignant melanoma metastatic to the eye, lids, and orbit. Surv Ophthalmol. 2008;53:187\u2013202.","journal-title":"Surv Ophthalmol"},{"key":"3753_CR17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/pcmr.12544","volume":"30","author":"NR Adler","year":"2017","unstructured":"Adler NR, Haydon A, McLean CA, Kelly JW, Mar VJ. Metastatic pathways in patients with cutaneous melanoma. Pigment Cell Melanoma Res. 2017;30:13\u201327.","journal-title":"Pigment Cell Melanoma Res"},{"key":"3753_CR18","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ophtha.2019.09.018","volume":"127","author":"JH Francis","year":"2020","unstructured":"Francis JH, Berry D, Abramson DH, Barker CA, Bergstrom C, Demirci H, et al. Intravitreous cutaneous metastatic melanoma in the era of checkpoint inhibition: unmasking and masquerading. Ophthalmology. 2020;127:240\u20138.","journal-title":"Ophthalmology"},{"key":"3753_CR19","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1159\/000488708","volume":"5","author":"L Everett","year":"2019","unstructured":"Everett L, Damato BE, Bloomer MM, Palmer JD, Kao AA, Stewart JM, et al. Metastatic cutaneous melanoma presenting with choroidal metastasis simulating primary uveal melanoma. Ocul Oncol Pathol. 2019;5:135\u20138.","journal-title":"Ocul Oncol Pathol"},{"key":"3753_CR20","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1159\/000521199","volume":"12","author":"JM Rieth","year":"2021","unstructured":"Rieth JM, Bowen RC, Milhem MM, Boldt HC, Binkley EM. Presumed Melanoma of unknown primary origin metastatic to the choroid mimics primary uveal melanoma. Case Rep. Ophthalmol. 2021;12:987\u201393.","journal-title":"Case Rep. Ophthalmol"},{"key":"3753_CR21","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1158\/2326-6066.CIR-18-0067","volume":"6","author":"JB Iorgulescu","year":"2018","unstructured":"Iorgulescu JB, Harary M, Zogg CK, Ligon KL, Reardon DA, Hodi FS, et al. Improved risk-adjusted survival for melanoma brain metastases in the era of checkpoint blockade immunotherapies: results from a national cohort. Cancer Immunol Res. 2018;6:1039\u201345.","journal-title":"Cancer Immunol Res"},{"key":"3753_CR22","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1186\/s12885-018-4470-y","volume":"18","author":"MA McDonald","year":"2018","unstructured":"McDonald MA, Sanghvi P, Bykowski J, Daniels GA. Unmasking of intracranial metastatic melanoma during ipilimumab\/nivolumab therapy: case report and literature review. BMC Cancer. 2018;18:549.","journal-title":"BMC Cancer"},{"key":"3753_CR23","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/S0161-6420(98)94011-8","volume":"105","author":"K G\u00fcnd\u00fcz","year":"1998","unstructured":"G\u00fcnd\u00fcz K, Shields JA, Shields CL, Eagle RC. Cutaneous melanoma metastatic to the vitreous cavity. Ophthalmology. 1998;105:600\u20135.","journal-title":"Ophthalmology"},{"key":"3753_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2022.101519","volume":"26","author":"JH Francis","year":"2022","unstructured":"Francis JH, Canestraro J, Abramson DH, Barker CA, Shoushtari AN. Combination intravitreous melphalan and bevacizumb for cutaneous metastatic melanoma to the vitreous and retina. Am J Ophthalmol Case Rep. 2022;26:101519.","journal-title":"Am J Ophthalmol Case Rep"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03753-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03753-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03753-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T12:23:56Z","timestamp":1748867036000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03753-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["3753"],"URL":"https:\/\/doi.org\/10.1038\/s41433-025-03753-x","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,25]]},"assertion":[{"value":"10 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}